Systems medicine advances in interstitial lung disease
Open Access
- 27 September 2017
- journal article
- review article
- Published by European Respiratory Society (ERS) in European Respiratory Review
- Vol. 26 (145) , 170021
Abstract
Fibrotic lung diseases involve subject–environment interactions, together with dysregulated homeostatic processes, impaired DNA repair and distorted immune functions. Systems medicine-based approaches are used to analyse diseases in a holistic manner, by integrating systems biology platforms along with clinical parameters, for the purpose of understanding disease origin, progression, exacerbation and remission.Interstitial lung diseases (ILDs) refer to a heterogeneous group of complex fibrotic diseases. The increase of systems medicine-based approaches in the understanding of ILDs provides exceptional advantages by improving diagnostics, unravelling phenotypical differences, and stratifying patient populations by predictable outcomes and personalised treatments. This review discusses the state-of-the-art contributions of systems medicine-based approaches in ILDs over the past 5 years.Keywords
This publication has 52 references indexed in Scilit:
- TOLLIP , MUC5B , and the Response to N -Acetylcysteine among Individuals with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2015
- An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial PneumoniasAmerican Journal of Respiratory and Critical Care Medicine, 2013
- Association Between the MUC5B Promoter Polymorphism and Survival in Patients With Idiopathic Pulmonary FibrosisJAMA, 2013
- Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association studyThe Lancet Respiratory Medicine, 2013
- Personalized Medicine: Applying ‘omics’ to Lung FibrosisBiomarkers in Medicine, 2012
- New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosisThe Lancet, 2012
- Ten Challenges for Systems MedicineFrontiers in Genetics, 2012
- Evolving Genomic Approaches to Idiopathic Pulmonary Fibrosis: Moving Beyond GenesClinical and Translational Science, 2011
- A CommonMUC5BPromoter Polymorphism and Pulmonary FibrosisNew England Journal of Medicine, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011